FMP

FMP

Enter

MDT - Medtronic plc

photo-url-https://images.financialmodelingprep.com/symbol/MDT.png

Medtronic plc

MDT

NYSE

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

83.48 USD

-0.14 (-0.168%)

Historical Prices

From:

To:

83.483.683.88484.209:30 AM09:50 AM10:10 AM10:30 AM10:50 AM11:10 AM11:30 AM11:50 AM12:10 PM12:30 PM12:50 PM01:10 PM01:30 PM01:50 PM02:10 PM02:30 PM02:50 PM03:10 PM03:30 PM03:50 PM

About

ceo

Mr. Geoffrey Straub Martha

sector

Healthcare

industry

Medical - Devices

exchange

NYSE

Description

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The compan...

CIK

0001613103

ISIN

IE00BTN1Y115

CUSIP

G5960L103

Address

20 On Hatch

Phone

353 1 438 1700

Country

IE

Employee

95,000

IPO Date

May 2, 1973

Financial Statement

02B4B6B8B10B2024 Q32024 Q42025 Q12025 Q22025 Q3RevenueNet Income

Earnings

00.30.60.91.21.51.82023 Q32023 Q42024 Q12024 Q22024 Q32024 Q42025 Q12025 Q2EPS Consensus

MDT Financial Summary

CIK

0001613103

Exchange

NYSE

Industry

Medical - Devices

Sector

Healthcare

CUSIP

G5960L103

ISIN

IE00BTN1Y115

Country

IE

Price

83.48

Beta

0.83

Volume Avg.

7.7M

Market Cap

107.07B

Shares

-

52-Week

75.96-96.25

DCF

117.31

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

25.45

P/B

-

Website

https://www.medtronic.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest MDT News

Davit Kirakosyan

Feb 18, 2025

Medtronic Plunges 7% After Mixed Q3 Results

Medtronic (NYSE:MDT) reported third-quarter earnings that exceeded analyst expectations, though revenue fell short. As a result, shares dropped more than 7% intra-day today. Despite the mixed results, the medical device maker reaffirmed its full-year guidance, citing continued strength across key business segments. For the quarter, Medtronic posted adjusted earnings per share of $1.39, surpassing the consensus estimate of $1.36. Revenue reached $8.29 billion, slightly below analysts’ forecasts o...

Gordon Thompson

Feb 18, 2025

Medtronic plc (NYSE: MDT) Surpasses Earnings Estimates

Medtronic plc (NYSE: MDT) is a global leader in medical technology, services, and solutions. The company operates in various segments, including cardiovascular, diabetes, and minimally invasive therapies. Medtronic's competitors include companies like Boston Scientific and Abbott Laboratories. On February 18, 2025, Medtronic reported earnings per share (EPS) of $1.39, surpassing the estimated $1.36, showcasing its strong financial performance. The company's revenue for the quarter was approxima...

Alex Lavoie

Feb 14, 2025

Medtronic's Upcoming Earnings Report: A Financial Overview

Medtronic (NYSE:MDT) is a leading global healthcare technology company, known for its innovative medical devices and therapies. As it prepares to release its quarterly earnings on February 18, 2025, investors are closely watching the company's financial performance. Analysts expect an earnings per share (EPS) of $1.36 and revenue of $8.32 billion, reflecting growth from the previous year. Medtronic's stock recently closed at $92.20, a 0.93% increase from the previous day, though it lagged behin...

Andrew Wynn

Nov 20, 2024

Medtronic's (NYSE:MDT) Latest Earnings Overview

Medtronic (NYSE:MDT) is a leading global healthcare technology company that specializes in medical devices and therapies. It operates in various segments, including cardiovascular, diabetes, and surgical technologies. Medtronic competes with other major players in the medical device industry, such as Johnson & Johnson and Boston Scientific. The company is known for its innovative products and solutions that improve patient outcomes. On November 19, 2024, Medtronic reported earnings per share (E...

The Motley Fool

Aug 26, 2024

This Is Great News for Medtronic, but Is It Time to Buy the ...

Medtronic delivered a strong first-quarter earnings report. The company benefits from continued market adoption of several new product launches over the past year.

Seeking Alpha

Aug 25, 2024

Medtronic: Is The Company Back?

Medtronic faced challenges, including poor focus, lack of innovation, and COVID-19 impact, leading to share price stagnation since 2018. Despite recent improvements in performance, Medtronic remains undervalued with solid competitive advantages and a promising dividend streak. The company's focus on innovation, strong market position, and dividend growth potential make it a long-term buy for conservative investors.

MarketBeat

Aug 23, 2024

Diabetes and Neuro Products Ignite Medtronic's Q1 Earnings R...

Shares of medical device manufacturer Medtronic PLC NYSE: MDT are down about 35% from their highs of roughly three years ago, but promising results from the company's first quarter of fiscal 2025, which ended July 26, could help to drive renewed upward momentum. Specifically, Medtronic's diabetes and neuromodulation products may be poised for breakout growth, and the company's up-and-coming products in various stages of development offer promise as well.

Forbes

Aug 22, 2024

What's Next For Medtronic Stock After An Upbeat Q1?

Medtronic (NYSE: MDT) recently reported its Q1 fiscal 2025 results (fiscal ends in April), with revenues and earnings exceeding our estimates. The company reported revenue of $7.9 billion and adjusted earnings of $1.23 per share, compared to our estimates of $7.9 billion and $1.21, respectively.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep